KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Amortization of Deferred Charges (2017 - 2025)

Historic Amortization of Deferred Charges for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $5.0 million.

  • Amneal Pharmaceuticals' Amortization of Deferred Charges fell 3734.43% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year decrease of 523.68%. This contributed to the annual value of $29.1 million for FY2024, which is 15196.57% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $5.0 million for Q3 2025, which was down 3734.43% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $8.0 million in Q3 2024 and a low of $2.1 million during Q1 2023
  • Its 5-year average for Amortization of Deferred Charges is $4.1 million, with a median of $2.4 million in 2021.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Amortization of Deferred Charges soared by 24002.54% in 2024, and later crashed by 3734.43% in 2025.
  • Amneal Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $2.3 million in 2021, then decreased by 9.61% to $2.1 million in 2022, then surged by 121.46% to $4.7 million in 2023, then skyrocketed by 46.16% to $6.8 million in 2024, then decreased by 26.21% to $5.0 million in 2025.
  • Its Amortization of Deferred Charges was $5.0 million in Q3 2025, compared to $6.9 million in Q2 2025 and $6.8 million in Q1 2025.